This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|August 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-08-01-2011
- Volume 23
- Issue 8
Controlled Release from Porous Platforms
The authors present a method for controlling the release of therapeutics by applying a plasma polymer layer to the surface of porous materials.
Advertisement
By Spomenka Simovic, Dusan Losic and Krasimir Vasilev
The authors present a method for controlling the release of therapeutics by applying a plasma polymer layer to the surface of porous materials. The current study applied this technique to the release of antibiotics and a protein. The approach substantially reduced the initial burst release and provided zero-order release kinetics. The method can be applied to any type of porous drug carrier because the techniques for depositing a polymer overlayer are independent of the substrate.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
about 15 years ago
Improving API Synthesisabout 15 years ago
Understanding Fluidized-Bed Granulationabout 15 years ago
Controlled Crystallization During Freeze-Dryingabout 15 years ago
Movin' On Outabout 15 years ago
The Many Varieties Of 'Emerging'about 15 years ago
Newsabout 15 years ago
Managing Information Overloadabout 15 years ago
The Importance Of Filter Testingabout 15 years ago
Making A Mark In Emerging Marketsabout 15 years ago
Croatia, Pharma and CorruptionAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement